Tevogen Bio Stock Price, News & Analysis

Tevogen (Nasdaq: TVGN) provided an update on its investigational precision T cell therapy TVGN 489 on Oct 15, 2025, citing growing public interest from Long COVID patients and stakeholders.

The company said a dose-finding clinical trial showed a favorable safety profile and was peer-reviewed and published in Blood Advances. Tevogen plans collaborations with government programs, patient organizations, and major healthcare providers to expedite development and access when regulatory pathways permit, and has created a dedicated Long COVID contact at longCOVID@tevogen.com. The company also stated it is maximizing capital efficiency and maintains access to financing to support advancement toward commercialization.

Tevogen (NASDAQ:TVGN) announced significant advancements in its PredicTcell™ AI platform for T cell-based therapies. The beta version has expanded its training dataset to ~1.4 million records and total dataset to over 6.7 billion records, marking a 100-fold increase.

The platform, developed with Microsoft and Databricks, builds upon the alpha version which achieved 92-97% recall levels and 38-43% precision. The beta version analyzes over 10.7 billion data points, including 6.5 billion virology, 4.2 billion genomic, and 416 million oncology datapoints, while expanding training features from 22 to 27.

This advancement could potentially enable T-cell therapies to bind to their targets with unprecedented accuracy, promising increased clinical success rates, shorter development timelines, and improved patient access to life-saving therapies.

Tevogen Bio (NASDAQ:TVGN) has highlighted the potential of its investigational T cell therapy TVGN 489 in treating Long COVID, which affects an estimated 20 million Americans. Recent peer-reviewed studies have linked Long COVID to persistent viral reservoirs, where SARS-CoV-2 proteins and RNA remain in the body for months to years after infection.

TVGN 489, developed using Tevogen's ExacTcell™ platform, is an off-the-shelf cytotoxic CD8+ T lymphocyte therapy targeting multiple SARS-CoV-2 proteins. In proof-of-concept trials, the therapy demonstrated efficacy in reducing viral load in all patients, with CTLs persisting for at least 6 months without interfering with patients' immune responses.

The company is actively preparing for clinical manufacturing of TVGN 489, which could potentially restore homeostasis in Long COVID patients by eliminating virus-infected cells.

Tevogen Bio (NASDAQ:TVGN) has acknowledged the U.S. Department of Health and Human Services' (HHS) initiative to address Long COVID through two focused roundtables. The company highlighted that approximately 20 million U.S. adults are affected by Long COVID, significantly impacting workforce participation and national productivity.

The company's investigational drug TVGN 489 has shown promising results in a Proof-of-Concept clinical trial. Tevogen is developing this therapy through its proprietary ExacTcell™ platform, which enables rapid development of genetically unmodified precision T cell therapies. The company aims to create accessible and affordable personalized therapeutics for Long COVID patients.

Tevogen Bio Holdings (Nasdaq: TVGN) announced that its Chief Information Officer and Head of Tevogen.AI, Mittul Mehta, will participate in the Startup Forum panel at the Databricks DATA + AI World Tour on October 8, 2025, in Boston.

The panel will focus on how early-stage companies are scaling with Databricks, featuring industry leaders including Chris Gervais from Codametrix and Stavros Papadopoulos from TileDB. Mehta will discuss Tevogen.AI's PredicTcell™ platform, developed with Microsoft and Databricks, which aims to accelerate precision immunotherapy development.

Tevogen (NASDAQ:TVGN) has announced promising financial projections for its pipeline product TVGN 116, targeting liver cancer prevention in high-risk chronic Hepatitis B patients. The company estimates a substantial 5-year cumulative top-line revenue of approximately $6.5 billion.

The risk-adjusted Net Present Value (rNPV) for TVGN 116 is projected to exceed $325 million in the US market alone. These projections are based on current market analysis and unmet medical needs. The company's development approach emphasizes a unique, accelerated, and cost-efficient drug development model, which they believe could serve as a template for sustainable medical innovation.

The success of their first clinical-stage product, TVGN 489, demonstrates the company's ability to rapidly achieve development milestones, with risk adjustments being reset at each milestone in the product development lifecycle.

Tevogen (Nasdaq: TVGN) has announced a risk-adjusted net present value (rNPV) of $9-11 billion for TVGN-489, its first clinical-stage allogeneic precision T cell therapy from the ExacTcell™ platform. The therapy targets SARS-CoV-2 infection in high-risk patients and Long-COVID cases.

Phase I clinical trial results published in Blood Advances demonstrated significant efficacy: 92% of patients showed ≥88% viral elimination by Day 4, and 100% achieved >99% elimination by Day 14. The treatment showed excellent safety with no major adverse events and maintained effectiveness against viral mutations, including the XFG variant.

Notably, two cancer patients successfully underwent stem cell transplants shortly after TVGN-489 treatment without COVID-19 complications, suggesting thorough viral eradication. The valuation reflects US-only revenue potential and excludes the broader ExacTcell™ platform value.

Tevogen (NASDAQ:TVGN) has revealed significant valuation metrics for its pipeline product TVGN 930, targeting EBV-associated leukemia and lymphomas. The company projects a risk-adjusted Net Present Value (rNPV) exceeding $250 million in the US market alone, with an estimated 5-year cumulative revenue forecast of $3.5 billion.

The therapeutic candidate addresses an accessible US market of up to 40,000 patients across five rare disease indications. Notably, TVGN 930 aims to fill a significant therapeutic gap, as there are currently no approved EBV vaccines or effective treatments. The company's development approach leverages a unique, faster, and cost-efficient drug development model.

Tevogen (NASDAQ:TVGN) emphasized the ongoing importance of SARS-CoV-2 treatments for immunocompromised individuals, highlighting their TVGN 489 investigational therapy. The treatment, developed using the ExacTcell platform, showed promising results in clinical trials.

Key trial findings revealed that TVGN 489 achieved >99% viral elimination in all patients by day 14, with CTLs persisting through six months of follow-up. The therapy demonstrated faster symptom resolution compared to standard care and was well-tolerated across all dose levels. Notably, the treatment's targets remain unaffected by mutations, including the current XFG variant.